Newly launched Visiongain report: Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

“Biosimilar mAb Market Share by compound by 2028”
Biosimilars MaB Report covers the following; Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 74 figures– all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.


FRree report overview?

Please email or call her on +44 207 5499987


Report Scope

Global Biosimilar Monoclonal Antibodies Market forecasts from 2018-2028

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2028 for the market segmented by compound:
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab

• This report also shows revenue to 2028 for individual biosimilar mAb products in the market:
• Remsima/Inflectra
• Infimab
• Reditux
• BI695500
• CT-P10
• BI695501
• FKB327
• FKB238
• Mabtas
• AcellBia
• Maball
• Clotinab
• Abcixirel
• BCD-022
• BCD-021
• Herzuma
• CANMAB/Hertraz


Download free sample pages of this report?

Click here:


• Our analyses show individual revenue forecasts to 2028 for these regional and national markets:
• The US Biosimilar mAb Market
• Japanese Biosimilar mAb Market
• EU5 Biosimilar mAb Markets
• BRIC and South Korea Biosimilar mAb Markets
• Rest of the World Biosimilar mAb Market

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.


Download free sample pages of this report?

Click here:

Media Contact
Company Name: Visiongain Limited
Contact Person: Sara Peerun
Email: Send Email
Phone: +44 207 3366100
Address:143 Airport House, Purley way
City: London CR0 0XZ
Country: United Kingdom